GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT04138043
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSVPreF3 formulation 3Drug: PlaceboBiological: Boostrix-ex-USBiological: RSVPreF3 formulation 2Biological: Boostrix-US
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 509
- Registration Number
- NCT04138056
- Locations
- 🇨🇦
GSK Investigational Site, London, Ontario, Canada
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04136145
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: GSK3196165 (Otilimab)Biological: SarilumabDrug: csDMARDs
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 550
- Registration Number
- NCT04134728
- Locations
- 🇬🇧
GSK Investigational Site, Northwood, Middlesex, United Kingdom
Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level
Phase 3
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 806
- Registration Number
- NCT04133909
- Locations
- 🇬🇧
GSK Investigational Site, Wishaw, United Kingdom
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
Terminated
- Conditions
- Neoplasms, Head and Neck
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 315
- Registration Number
- NCT04128696
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 2
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants
Phase 2
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: RSV MAT 60 µgBiological: RSV MAT 120 µgDrug: Placebo
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 534
- Registration Number
- NCT04126213
- Locations
- 🇪🇸
GSK Investigational Site, Marbella, Spain
A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride
Phase 3
Completed
- Conditions
- Gingivitis
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 98
- Registration Number
- NCT04123665
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT04114656
- Locations
- 🇳🇱
GSK Investigational Site, Leiden, Netherlands
© Copyright 2025. All Rights Reserved by MedPath